PD-0299685

PD-0299685

Clinical data
Other names	PD-0299685; PD-299685; PD0299685; PD299685; PD-299,685
Routes of administration	Oral[1]
Drug class	Gabapentinoid
ATC code	None
Identifiers
IUPAC name (3S,5R)-3-(aminomethyl)-5-methyloctanoic acid
CAS Number	313651-33-1
PubChem CID	10149052
DrugBank	DB15264
ChemSpider	8324560
UNII	61SA6645RL
ChEMBL	ChEMBL4297316
Chemical and physical data
Formula	C10H21NO2
Molar mass	187.283 g·mol^−1
3D model (JSmol)	Interactive image
SMILES CCC[C@@H](C)C[C@@H](CC(=O)O)CN
InChI InChI=1S/C10H21NO2/c1-3-4-8(2)5-9(7-11)6-10(12)13/h8-9H,3-7,11H2,1-2H3,(H,12,13)/t8-,9+/m1/s1 Key:KKXFMWXZXDUYBF-BDAKNGLRSA-N

PD-0299685 is a gabapentinoid (α₂δ subunit-containing voltage-gated calcium channel blocker) which was under development for the treatment of insomnia and vasomotor symptoms (hot flashes) related to menopause as well as interstitial cystitis.^[1][2][3] It is taken orally.^[1] PD-0299685 was under development by Pfizer.^[1] It reached phase 2 clinical trials prior to the discontinuation of its development.^[1]

See also

• List of investigational insomnia drugs
• Atagabalin (PD-0200390)

References

1. "PD 0299685". AdisInsight. 5 November 2023. Retrieved 3 October 2025.
2. Lewis V (November 2009). "Undertreatment of menopausal symptoms and novel options for comprehensive management". Current Medical Research and Opinion. 25 (11): 2689–2698. doi:10.1185/03007990903240519. PMID 19775194.
3. Nickel JC, Crossland A, Davis E, Haab F, Mills IW, Rovner E, et al. (September 2012). "Investigation of a Ca2+ channel α2δ ligand for the treatment of interstitial cystitis: results of a randomized, double-blind, placebo controlled phase II trial". The Journal of Urology. 188 (3): 817–823. doi:10.1016/j.juro.2012.05.010. PMID 22818144.